Table 2.
FDA-approved immune checkpoint inhibitors (ICIs) for the treatment of stage III/IV NSCLC.
| ICI Treatment | Pivotal Trial | Setting | Target Population | FDA Approval |
|---|---|---|---|---|
| Nivolumab monotherapy versus docetaxel | CheckMate017 | II line after chemotherapy failure | Stage III-B or IV Squamous NSCLC | March 2015 |
| Nivolumab monotherapy versus docetaxel | CheckMate057 | II line after chemotherapy failure | Stage III-B or IV Nonsquamous NSCLC | October 2015 |
| Pembrolizumab monotherapy versus platinum- based chemotherapy | KEYNOTE-024 | I line (PD-L1 ≥ 50%) | Stage IV Nonsquamous and squamous NSCLC | October 2016 |
| Pembrolizumab monotherapy versus docetaxel | KEYNOTE-010 | II line after chemotherapy failure (PD-L1 ≥ 1%) | Nonsquamous and squamous NSCLC | October 2016 |
| Atezolizumab monotherapy | OAK | II line after chemotherapy failure | Stage III-B or IV Nonsquamous and squamous NSCLC | October 2016 |
| Durvalumab monotherapy versus placebo | PACIFIC | Durvalumab after chemoradiotherapy | Stage III unresectable Nonsquamous and squamous NSCLC | February 2018 |
| Pembrolizumab + cis/carboplatin + pemetrexed | KEYNOTE-189 | I line | Nonsquamous NSCLC | August 2018 |
| Pembrolizumab + paclitaxel/nab-paclitaxel + carboplatin | KEYNOTE-407 | I line | Stage IV Squamous NSCLC | October 2018 |
| Atezolizumab + carboplatin + paclitaxel + bevacizumab | IMpower 150 | I line | Stage IV or recurrent metastatic Nonsquamous NSCLC | December 2018 |
ALK: anaplastic lymphoma kinase; CNS: central nervous system; ECOG PS: Eastern Cooperative Oncology Group Performance Status; EGFR: epidermal growth factor receptor; ICI: immune checkpoint inhibitor; NR: not reached; NSCLC: non-small cell lung cancer; OS: overall survival; PFS: progression free survival; TKI: tyrosine kinase inhibitor.